CLINICAL_TRIALS
trial_result
· 2013-05-14
Clinical Trial Update: Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. [Phase 1]
Summary
Phase 1 study of MDX-1411 given every 14 days with pre-medications in clear cell renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Kidney Cancer | Phase 1 | Status: COMPLETED